Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 125 Neoplasm Metastasis 17 Ovarian Neoplasms 12 Endometrial Neoplasms 9 Neoplasms 8 Triple Negative Breast Neoplasms 7 Carcinoma, Non-Small-Cell Lung 6 Uterine Cervical Neoplasms 5 Prostatic Neoplasms 5 Hereditary Sensory and Autonomic Neuropathies 5 Colorectal Neoplasms 5 Advanced Breast Cancer 5 Squamous Cell Carcinoma of Head and Neck 4 Stomach Neoplasms 3 Recurrence 3 Neoplasms by Site 3 Head and Neck Neoplasms 3 Carcinoma, Lobular 3 Breast Diseases 3 Breast Cancer Metastatic 3 Uterine Neoplasms 2 Small Cell Lung Carcinoma 2 Multiple Endocrine Neoplasia Type 1 2 Melanoma 2 Locally Advanced (Inoperable) or Metastatic Breast Cancer 2 Fallopian Tube Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Advanced Solid Tumors 2 Urologic Neoplasms 1 Urogenital Neoplasms 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Fulvestrant × 1 year × Clear all

NCT06998407 2026-05-04

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡